Sodium-Glucose Cotransporter 2 Inhibitors for Repaired Tetralogy of Fallot Patients for Enhancement of Cardio-Pulmonary Status Trial

A phase 4 trial registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 106 participants.

Also called NCT06668389

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; no masking; primary purpose treatment
Phase
Phase 4
Enrolled
  • 106 participants (planned count) (from the registry)
Sponsor
Registry
  • NCT NCT06668389
Started
(actual) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
Hong Kong SAR China (from the registry)
Registry status
  • Recruiting (from the registry)

Technical summary

Registry record NCT06668389. Randomized; no masking; primary purpose treatment. Start 2025-05-12 (actual); primary completion 2026-12-31 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Sodium-Glucose Cotransporter 2 Inhibitors for Repaired Tetralogy of Fallot Patients for Enhancement of Cardio-Pulmonary Status Trial
Acronym
STEPS
Condition
Congenital Heart Disease
Condition
Repaired Tetralogy of Fallot (rTOF)
Condition
Pulmonary Regurgitation
Condition
Sodium-glucose Cotransporter 2 (SGLT2) Inhibitor
Condition
Dapagliflozin (Forxiga)
Intervention (Drug)
SGLT2 inhibitor (Dapagliflozin 10mg)
Lead sponsor
The University of Hong Kong (class: other)

Record details

Record id
cardio:ct-nct06668389
Content hash
2d0e2f3c6d9ae59b1e4cb28bdf64e14bd221edfc8893c099bbe649d5cce22ee6